Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Ermenegildo Zegna NV
ZGN
5
Precision Drilling
PDS
US OptionsDetailed Quotes
IOVA250509C4500
- 0.05
- 0.000.00%
15min DelayClose May 9 15:55 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume1.22K Open Interest4.50Strike Price0.00Turnover0.00%IV154.19%PremiumMay 9, 2025Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma35.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Iovance Biotherapeutics Newsroom
Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating, Maintains Target Price $5
Iovance Biotherapeutics Is Maintained at Outperform by Mizuho
Iovance Biotherapeutics Price Target Cut to $10.00/Share From $30.00 by Mizuho
Iovance Biotherapeutics Analyst Ratings
Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $4
Truist Financial Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating, Cuts Target Price to $5
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA)
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $20
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $25
Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10
Iovance Biotherapeutics Cut to Market Perform From Market Outperform by JMP Securities
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), GH Research (GHRS) and NewAmsterdam Pharma Company (NAMS)
Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20
Iovance Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
Iovance Biotherapeutics Price Target Cut to $20.00/Share From $32.00 by HC Wainwright & Co.
Citizens JMP Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $5
Iovance Biotherapeutics Is Maintained at Buy by Goldman Sachs
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $16
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $5
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
